Clinical trial NCT01633177: Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes
Official title: Diabetes Prevention in the Vitamin D and Omega-3 Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Type 2 Diabetes
Keywords: vitamin D
omega-3 fatty acids
Type 2 diabetes
Oral glucose tolerance test (OGTT)
Insulin sensitivity
Beta-cell function
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2012-07-04
Enrollment: 25875
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among nondiabetic participants in VITAL and will examine whether vitamin D or fish oil prevent type 2 diabetes. Findings from this proposed study conducted within the VITAL trial will clarify whether vitamin D and omega-3 fatty acid supplementation reduces risk of type 2 diabetes and thus will inform public health and clinical guidelines for diabetes prevention.

Detailed description: Emerging evidence suggests favorable effects of both vitamin D and marine omega-3 fatty acids on glucose homeostasis. Optimal vitamin D intake is essential for insulin secretion and action, and omega-3 fatty acids may reduce diabetes risk as a result of favorable effects on insulin sensitivity, endothelial function, chronic inflammation, or other metabolic abnormalities. Although the metabolic effects of vitamin D and omega-3 fatty acids show considerable promise for the primary prevention of type 2 diabetes (T2D), there are no completed, ongoing, or planned randomized clinical trials of vitamin D or omega-3 supplements that include T2D as a primary outcome in a general population.

We thus propose to utilize an NIH-funded randomized trial (1 U01 CA138962) to test the hypothesis that vitamin D and omega-3 supplementation will reduce the risk of T2D. We will further assess whether and to what extent vitamin D or omega-3 supplementation will improve insulin sensitivity and pancreatic beta-cell function in a subsample of the trial cohort. The VITamin D and OmegA-3 TriaL (VITAL) is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the benefits and risks of vitamin D3 (2,000 IU/day) and marine omega-3 fatty acid (eicosapentaenoic acid \[EPA\] + docosahexaenoic acid \[DHA\], 1g/day) supplements in the primary prevention of cancer and cardiovascular disease (CVD). The VITAL trial will aim to enroll 20,000 men and women (aged ≥50 and ≥55 years, respectively). The planned treatment duration is 5 years after a 1.5-year recruitment period. This diabetes ancillary study aims to implement an inexpensive and efficient strategy to validate self-reported incident T2D cases in the entire trial population and to collect pre- and post-intervention measures of glucose, insulin, and hemoglobin A1c (HbA1c) in a subset of participants. Two methods of diabetes case validation are proposed. First, we plan to collect detailed information about diagnostic glucose testing and anti-diabetic medication use from medical records and/or supplementary questionnaires completed by the participant's physician. Second, to complement our diabetes ascertainment process, we will also plan to retrieve additional data on diabetes diagnoses and hypoglycemic medications by linking the participants with the Centers for Medicare and Medicaid Services (CMS) database. In addition to evaluating whether the study interventions impact the onset of clinical diabetes, we propose to collect pre- and post-intervention measures of glucose, insulin, and HbA1c in a subset of the participants to reliably assess whether vitamin D or omega-3 supplementation alters insulin and glucose homeostasis. We plan to recruit 1,000 participants without prior clinical diabetes at the Clinical and Translational Science Center (CTSC) site at Brigham and Women's Hospital. A standard 2-hour oral glucose tolerance test (OGTT) and HbA1c measurements will be performed during the CTSC visits at baseline and at 2-year post-randomization.

Primary Aims:

1. To test whether vitamin D3 and/or EPA+DHA supplementation reduces the risk of T2D among all initially non-diabetic participants in the VITAL trial.
2. To test whether vitamin D3 and/or EPA+DHA supplementation improves insulin sensitivity and beta-cell function in a subset of 1,000 non-diabetic participants receiving OGTT at baseline and 2-year post-randomization.

Secondary Aims:

1. To test whether vitamin D3 and/or EPA+DHA supplementation lowers HbA1c, fasting glucose and insulin, as well as other surrogate indices of insulin sensitivity and beta-cell function as determined by the homeostasis model assessment (HOMA-IR and HOMA-%B, respectively) in our substudy.
2. To test whether vitamin D3 and EPA+DHA supplementation exerts synergistic or additive effects on the risk of T2D among all initially non-diabetic participants in the VITAL trial.
3. To test whether vitamin D3 and EPA+DHA supplementation exerts synergistic or additive effects on insulin sensitivity and beta-cell function as assessed by OGTT in our substudy.

For the above main effect estimates, we will further explore whether the effect of vitamin D3 or EPA+DHA supplementation varies by (1) age, (2) sex, (3) baseline intakes of these nutrients, (4) baseline levels of 25(OH)D (for vitamin D3), (5) race/skin pigmentation (for vitamin D3), (6) geographic region (for vitamin D3), and (7) BMI (for vitamin D3).

Eligibility criteria: Participants in VITAL (NCT01169259) who have no history of diabetes mellitus at baseline are eligible to participate in this ancillary study.

Primary outcomes:
measure: Incident type 2 diabetes
timeFrame: 5 years
Secondary outcomes:
measure: OGTT index of insulin sensitivity
timeFrame: 2 years
measure: OGTT index of beta-cell function
timeFrame: 2 years
measure: HbA1c levels
timeFrame: 2 years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Division of Preventive Medicine, Brigham and Women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Yiqing Song, MD, ScD
role: PRINCIPAL_INVESTIGATOR
References: